GlaxoSmithKline to Aide Novavax in Covid-19 Vaccine Manufacture
2021年3月30日 - 2:23AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC and Novavax Inc. said Monday that the two
companies have reached an agreement in principle with the U.K.
government to support the manufacturing of Novavax's coronavirus
vaccine in the U.K.
Glaxo, a British pharmaceutical company, said it will provide
fill-and-finish manufacturing capacity at its Barnard Castle
facility in England starting in May 2021. Fill and finish is
understood as the final stage of vaccine manufacturing, where vials
are prepared and packaged for distribution.
A "rapid" technology transfer between Glaxo and U.S.
pharmaceutical giant Novavax will begin immediately, the companies
said.
The U.K. government has secured 60 million vaccine doses under
an advance-purchase agreement with Novavax.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 29, 2021 13:08 ET (17:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024